What question did this study set out to answer?

To assess the impact of ticlopidine on neurologic outcomes and hemorheologic patterns in ischemic stroke patients during the postacute phase.

July 1, 1990Angiology

Effects of Ticlopidine on the Neurologic Outcome and the Hemorheologic Pattern in the Postacute Phase of Ischemic Stroke: A Pilot Study

View Full Paper

Ask AI

Bookmark

Why the study?

Does ticlopidine improve neurologic outcomes and hemorheologic parameters in patients with acute ischemic stroke?

Population

30 patients included within 12 hours of the onset of ischemic stroke, confirmed clinically and by…

Comparison

Ticlopidine 250 mg oral twice daily for 21 days. vs Placebo.

Design

RCT, double-blind

Follow-up

21 days

Authors

GCGiovańni CiuffettiUniversity of Perugia GAGiovanni AisaUniversity of Perugia MMMichele MercuriVascular Medicine

Discussion

Member takes

Implication

Supports ticlopidine for postacute ischemic stroke recovery; extends RCT evidence linking hemorheologic changes to neurologic gains.

Key Points

To assess the impact of ticlopidine on neurologic outcomes and hemorheologic patterns in ischemic stroke patients during the postacute phase.
Double-blind design with 15 patients receiving ticlopidine and 15 receiving placebo over 21 days.
Monitoring of neurologic scores using Hachinski's Scale and hemorheologic parameters weekly.
Inclusion of patients within 12 hours of ischemic stroke onset confirmed by computerized tomography.
Ticlopidine treatment improved neurologic outcomes by +36% on Hachinski's Score (p<0.03).
Significant increase in average whole blood filterability (+19%) and red cell filterability (+17%) (p<0.001).
Fibrinogen levels decreased by -17% with ticlopidine treatment.

Structured PICO

Does ticlopidine improve neurologic outcomes and hemorheologic parameters in patients with acute ischemic stroke?

Population

30 patients (age range 66 to 86 years) included within 12 hours of the onset of ischemic stroke, confirmed clinically and by computerized tomography.

Intervention

Ticlopidine 250 mg oral twice daily for 21 days.

Comparator

Placebo.

Outcome

Neurologic outcome (Hachinski's Scale) and hemorheologic parameters (fibrinogen levels, whole blood, unfractionated white and red blood cell filterability rates, leukocyte count and activation) monitored weekly for 21 days.surrogate

Ticlopidine administered within 12 hours of ischemic stroke onset improves neurologic outcomes and favorable hemorheologic parameters over 21 days.

Cite This Study

Ciuffetti et al. (1990) studied this question.

synapsesocial.com/papers/6a766ea3232067cbf2ec065f https://doi.org/10.1177/000331979004100701

View Full Paper

Ask AI

Bookmark

Effects of Ticlopidine on the Neurologic Outcome and the Hemorheologic Pattern in the Postacute Phase of Ischemic Stroke: A Pilot Study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Effects of Ticlopidine on the Neurologic Outcome and the Hemorheologic Pattern in the Postacute Phase of Ischemic Stroke: A Pilot Study

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider